



9700 Great Seneca Highway,
Suite 188, Rockville, MD 20850
Ph: 301-760-7307
Fx: 301-760-3951
<http://www.alperbiotech.com/>

15 January, 2008

Dear Friends and Colleagues,

After working for twenty-three years as a cancer researcher in academia, government and the private sectors in four countries including Turkey, Japan, Australia and the USA, I have started a biotechnology business here in Maryland. My new company, Alper Biotech, is focused on serving cancer researchers by providing new technologies that will significantly facilitate their research efforts in the battle against a number of the most pernicious cancers facing science. It is our hope that our technologies will contribute to new breakthroughs in cancer research as well as advancements in basic and translational research.

We have developed a group of unique monoclonal antibodies (MOABs) using a novel method against biomarkers that are in their natural conformation and secreted from cancerous or disease tissues into the blood stream. We think these MOABs will facilitate and catalyze cancer research given their pronounced sensitivity and specificity in detecting biomarkers in blood samples. Today, we are excited to introduce to the cancer research community our first MOAB in our MOAB group, Alper-pCBP-1. As more fully described in our webpage, this antibody detects soluble PCBP-1 in blood. Our data indicates that it is a putative metastatic breast cancer biomarker.

We are very eager to have you work with our MOABs and to give us your feedback about their performance and how we might serve you and the rest of the cancer research community better.

With my best regards,
Özge Alper, PhD
President